Source: Abstract # THU-248 No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies—C. Sarrazin et al.
Study Aims and Results: The study was a combination of two studies (POLARIS-1 & 4) looking at treating HCV genotype 1 through 6 (pan-genotypic) direct-acting treatment experienced patients with a combination of sofosbuvir, velpatasvir and voxilaprevir.
A total of 445 patients were treated for 12 weeks with the 3-drug combination. Thirty-one percent did not have resistant-associated substitutions (RASs) and the remainder had either one RASs or multiple RASs.
Conclusions: The overall cure rates were 97 to 100% regardless of genotype, cirrhosis/no cirrhosis, type of prior treatment failure or RASs. The 12-week treatment of this combination yields very high cure rates for people who have been previously treated with a direct-acting antiviral medication and who have single or single or double RASs.
Editorial Comments: This is good news for patients and medical providers. The triple combination of sofosbuvir, velpatasvir and voxilaprevir in a once-a-day dose is scheduled to be approved by the Food and Drug Administration (FDA) later this year. It will be a welcome addition to the growing list of HCV medical therapies that are pushing towards 100% cure rates even in people who have not achieved a cure with a prior course of HCV therapy and who have single and double RASs.
To read the June HCV Advocate newsletter, click hereShare This Page